Avalo Therapeutics (NASDAQ:AVTX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Avalo Therapeutics (NASDAQ:AVTX) from a strong sell rating to a hold rating in a research report report published on Sunday.

Several other brokerages have also recently weighed in on AVTX. BTIG Research reiterated a “buy” rating and set a $40.00 price target on shares of Avalo Therapeutics in a research report on Tuesday, March 24th. Guggenheim assumed coverage on Avalo Therapeutics in a research report on Monday, February 2nd. They issued a “buy” rating and a $50.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Friday, January 9th. HC Wainwright boosted their target price on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. Finally, Mizuho upgraded shares of Avalo Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Avalo Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $42.25.

Avalo Therapeutics Stock Performance

Shares of AVTX opened at $14.93 on Friday. The business’s 50-day moving average is $15.45 and its two-hundred day moving average is $15.89. The company has a market capitalization of $340.25 million, a P/E ratio of -2.61 and a beta of 0.84. Avalo Therapeutics has a fifty-two week low of $3.39 and a fifty-two week high of $20.72.

Avalo Therapeutics (NASDAQ:AVTX) last issued its quarterly earnings data on Monday, March 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.54) by $1.17. The company had revenue of $0.06 million during the quarter, compared to analyst estimates of ($0.21) million. Analysts forecast that Avalo Therapeutics will post -19.07 EPS for the current year.

Insiders Place Their Bets

In other Avalo Therapeutics news, insider Mittie Doyle sold 25,492 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $16.15, for a total transaction of $411,695.80. Following the transaction, the insider owned 3,622 shares in the company, valued at approximately $58,495.30. This represents a 87.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.25% of the company’s stock.

Institutional Trading of Avalo Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Velan Capital Investment Management LP grew its stake in Avalo Therapeutics by 38.4% in the 2nd quarter. Velan Capital Investment Management LP now owns 154,972 shares of the company’s stock valued at $773,000 after acquiring an additional 43,000 shares during the period. Patient Square Capital LP purchased a new stake in Avalo Therapeutics in the 3rd quarter worth $1,271,000. Cantor Fitzgerald L. P. acquired a new position in Avalo Therapeutics during the third quarter worth $1,083,000. Boothbay Fund Management LLC raised its position in Avalo Therapeutics by 1,916.6% during the third quarter. Boothbay Fund Management LLC now owns 228,297 shares of the company’s stock worth $2,902,000 after acquiring an additional 216,976 shares during the period. Finally, Ally Bridge Group NY LLC purchased a new position in Avalo Therapeutics during the third quarter valued at $2,264,000. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.